![](https://www.webhealthnetwork.com/img/webhealth-logo.png)
Myelofibrosis - 57 Studies Found
Completed |
: A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis : Primary Myelofibrosis (MF) : 2014-03-12 : Drug: Ruxolitinib |
Active, not recruiting |
: JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis : Myelofibrosis : 2012-12-21 : Drug: Ruxolotinib Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT f |
Active, not recruiting |
: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) : Myelofibrosis : 2012-09-14 :
|
Recruiting |
: Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis : Myelofibrosis : 2016-09-30 : Other: Hematopoietic Stem Cell Transplant This observational study will compare outcomes of prospectivel |
Recruiting |
: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis :
|
Completed |
: A Phase 2 Study With IPI-926 in Patients With Myelofibrosis :
: 2011-06-09 : Drug: IPI-926 Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive dise |
Completed |
: Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis :
: 2011-01-18 |
Completed |
: Ph II Study of Azacitidine in Myelofibrosis : Myelofibrosis : 2007-12-06 : Drug: Azacitidine 75 mg/m^2 subcutaneous daily for 7 days (every 4 week cycle) |
Recruiting |
: Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis :
|
Active, not recruiting |
: Study of Ruxolitinib for Patients With Myelofibrosis (MF) : Myelofibrosis : 2016-05-20 :
|